× Key messages Background DAPA-HF update Conclusions Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

DAPA-HF Update

Key messages

  • Dapagliflozin (an inhibitor of sodium-glucose cotransporter 2) leads to dramatic reductions in hospitalization for heart failure and mortality in subjects with and without diabetes: the benefits are clear in heart failure with reduced ejection fraction.
  • Dapagliflozin offers a new approach to improving symptoms, functional limitations, and quality of life on patients with heart failure and reduced ejection fraction.